VBIO Stock Catalyst: Valion Bio Successfully Formulates Oral Mucosal Entolimod with Shear Kershman Laboratories

Sep 30, 2026 · 7:45am ET

The collaboration marks a significant advancement in drug development.

Max move

+56.4%

High of day $4.32

Sparker timei

7:45am ET

VBIO · Sep 30, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Valion Bio, Inc. (Nasdaq: VBIO) and Shear Kershman Laboratories have announced the successful formulation of Oral Mucosal Entolimod. This development represents a key milestone in the ongoing collaboration between the two companies.

The formulation of Oral Mucosal Entolimod is expected to enhance the drug's delivery mechanism, potentially improving its efficacy and patient compliance. Valion Bio's free float stands at 4,068,246 shares.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time VBIO sparks.

Download Sniper App →

Catch the next VBIO-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →